Pre-Approval Access to Amivantamab in Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations who have Failed Platinum-Based Chemotherapy

Brief description of study

The purpose of this Expanded Access Program (EAP) is for patients with metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations (Exon20ins), and whose disease has progressed during or after current standard of care platinum-based chemotherapy. Eligible patients will receive the investigational drug Amivantamab, a fully-human, bispecific IgG1 antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptors. The study drug is investigational which means that the Food and Drug Administration (FDA) has not approved the drug for this use.

Clinical Study Identifier: s21-00053 Identifier: NCT04599712

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.